Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diagnostics
Use of biomarkers to detect cervical dysplasia, cancer a 'success'
December 16th, 2004
TriPath Imaging, Inc. (TPTH) announced that data from in-house studies of an early version of its multiple biomarkers demonstrated a sensitivity of 93%, a specificity of 92%, a negative predictive value of 97%, and a positive predictive value of 79%. These results were for biopsy proven moderate to severe cervical dysplasia in a retrospective cohort of cervical samples. These and other data relating to the performance of individual biomarkers and the proprietary formulation combining multiple biomarkers were presented at the 52nd Annual Scientific Meeting of the American Society of Cytopathology (ASC) in Chicago, Illinois, and support the potential...
Source: Women's Health Weekly (2004-12-16)
|
